Conference Proceeding Open Access

Cardiovascular and Renal Benefits of SGLT2 Inhibitors(Evidence-Based)

Abstract

Abstract: Type 2 diabetes mellitus (T2DM) is a worldwide growing public health problem that is associated with a high prevalence and a high mortality rate. Early good blood glucose control can reduce the risk of microvascular and macrovascular complications, including Cardiovascular Disease (CVD), diabetic nephropathy and mortality.Current hypoglycemic agents have demonestrated their effects either through direct insulin administration or agents that promote insulin secretion, improving insulin sensitivity, delaying the delivery and absorption of carbohydrate from the Gastrointestinal (GI)Tract. Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) approved by the US Food and Drug Administration (FDA) Since 2008. Trials have shown benefits with SGLT2 inhibitors that are not seen with other antihyperglycemic drugs to reduce cardiovascular events and reduce the progression of diabetic nephropathy. Bibliography: Maha A. AlMolaiki has completed her BSc.Pharm. and PharmD from King Saud University and has worked assisting as Patient Care, both in outpatient and inpatient at King Abdulaziz Medical City-Central region-Ministry of National Guard Health Affairs. She is currently an Internal Medicine Clinical Pharmacist at King Abdulaziz Medical City-Central Region-Ministry of National Guard Health affairs.

Maha A. AlMolaiki